Stryker Corporation
NYSE:SYKMedical - Devices
+$9.29 today
- Market cap
- $121.12B
- Beta
- 0.79
- P/E (TTM)
- 35.6
- EPS (TTM)
- $8.72
- Dividend yield
- 1.11%
Volume 3.25M
Average 2.49M
SYK EBITDA Margin
EBITDA as a percentage of revenue.
Stryker CorporationNYSE: SYK
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 30.4%
EBITDA Margin was 30.4% in Q2 FY2026, up 3.5 pp from a year earlier. On a trailing-twelve-month basis it was 25.9%, up 5.9 pp year over year. Over 3 fiscal years it widened by 3.4 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 20 analysts of 31.1% for the fiscal year ending Dec 2026, up from 25.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 30.4%+8.8 pp QoQ
- Last fiscal yearDec 2025
- 25.1%-1.4 pp YoY
- LTMJun 2026
- 25.9%+5.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.5 pp | +6.6 pp | +3.1 pp |
| 1 year | -1.4 pp | +6.0 pp | +7.4 pp |
| 3 years | +3.4 pp | +6.4 pp | +3.1 pp |
| 5 years | +7.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 25.1%
- Year-over-year change
- -1.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.1% | -1.4pp |
| FY2024 | 2024-12-31 | 26.6% | +1.9pp |
| FY2023 | 2023-12-31 | 24.7% | +2.9pp |
| FY2022 | 2022-12-31 | 21.8% | +0.7pp |
| FY2021 | 2021-12-31 | 21.1% | — |
EBITDA Margin vs competitors
How SYK compares with its peers on the latest reported figures
- SYK's LTM Jun 2026 EBITDA Margin of 25.9% is the 4th highest of the 11 companies compared; the peer median is 11.9%.
- Its year-over-year change of +5.9 pp is the 5th highest of 11, against a peer median of -0.6 pp.
- Over three fiscal years its change of +3.4 pp compares with a peer median of +0.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 30.1% | +6.5 pp | +0.4 pp | |
| LTM Jun 2026 | 27.5% | -1.6 pp | +5.4 pp | |
| LTM Jul 2026 | 27.3% | +0.0 pp | -0.9 pp | |
| LTM Jun 2026 | 25.9% | +5.9 pp | +3.4 pp | |
| FY2025 | 21.7% | -1.3 pp | -0.4 pp | |
| LTM Mar 2026 | 12.4% | -6.5 pp | +10.5 pp | |
| LTM Mar 2026 | 11.5% | +13.4 pp | -6.1 pp | |
| LTM Mar 2026 | 9.7% | +12.3 pp | +21.2 pp | |
| LTM Mar 2026 | -0.2% | +8.0 pp | +24.0 pp | |
| LTM Mar 2026 | -17.6% | -28.7 pp | -44.6 pp | |
| LTM Apr 2026 | -32.8% | -10.9 pp | -52.4 pp | |
| Peer median (excluding SYK) | 11.9% | -0.6 pp | +0.0 pp | |
Competitors are the stored peer set for SYK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.11B | 18.45B | 20.5B | 22.6B | 25.12B |
| Cost of Revenue | 6.4B | 7.41B | 8B | 8.05B | 9.05B |
| Gross Profit | 10.71B | 11.04B | 12.49B | 14.55B | 16.07B |
| Gross Margin | 62.6% | 59.8% | 61.0% | 64.4% | 64.0% |
| Research & Development | 1.13B | 1.23B | 1.29B | 1.47B | 1.58B |
| Selling, General & Admin | 5.81B | 6.08B | 6.92B | 7.5B | 8.65B |
| Operating Expenses | 6.95B | 7.31B | 8.21B | 10.86B | 11.18B |
| Depreciation & Amortization | 990M | 998M | 1.03B | 1.05B | 1.19B |
| EBITDA | 3.61B | 4.02B | 5.06B | 6.01B | 6.31B |
| EBITDA Margin | 21.1% | 21.8% | 24.7% | 26.6% | 25.1% |
| Operating Income | 3.76B | 3.73B | 4.28B | 3.69B | 4.89B |
| Operating Margin | 22.0% | 20.2% | 20.9% | 16.3% | 19.5% |
| Interest Income | 68M | 94M | 75M | 139M | 121M |
| Interest Expense | 337M | 337M | 356M | 396M | 607M |
| Other Income / Expenses | (1.48B) | (1.05B) | (608M) | (197M) | (375M) |
| Income Before Tax | 2.28B | 2.68B | 3.67B | 3.49B | 4.51B |
| Pre-Tax Margin | 13.3% | 14.5% | 17.9% | 15.5% | 18.0% |
| Income Tax Expense | 287M | 325M | 508M | 499M | 1.27B |
| Net Income | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
| Net Margin | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% |
| EPS (Basic) | 5.29 | 6.23 | 8.34 | 7.86 | 8.49 |
| EPS (Diluted) | 5.22 | 6.17 | 8.25 | 7.76 | 8.40 |
| Weighted Avg Shares | 377M | 378.2M | 379.6M | 381M | 382.2M |
| Weighted Avg Shares (Diluted) | 382.3M | 382.2M | 383.7M | 385.6M | 382.2M |
Stryker Corporation
NYSE:SYK
Intrinsic Alpha fair value
Locked
Current Price
$318.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.